Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted, but causes more toxicity. To address this, the multicentric PRIDE trial employs two cycles of bevacizumab to achieve dose escalation isotoxically. The goal is improved survival without significantly increasing side effects. The study uses a simultaneous integrated boost with a total dose of 75 Gy in 2.5 Gy per fraction.

NCT Number	NCT05871021
Lead Sponsor	University Hospital Tuebingen
Conditions	Glioblastoma
Enrollment	146 participants
Start Date	2024-04-10
Primary Completion	2028-04-10 (estimated)
Study Completion	2028-07-10 (estimated)
Updated on ClinicalTrials.gov	2026-05-18